We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

dinsdag 5 december 2017

Neuropsychopharmacology - Table of Contents alert Volume 43 Issue 1

If you are unable to see the message below, click here to view.
Neuropsychopharmacology
TABLE OF CONTENTS

Volume 43, Issue 1 (January 2018)

In this issue
Editorial
Review Articles
Hot Topics

Also new
AOP
 
Follow NPP on Facebook Facebook

Follow NPP on Twitter Twitter

Sign up for e-alerts Sign up for e-alerts
Recommend to your library
Web feed
Subscribe

Editorial

Top

Cannabis and Cannabinoids: From Synapse to Society

Margaret Haney and Matthew N Hill

Neuropsychopharmacology 2018 43: 1-3; 10.1038/npp.2017.255

Full Text

Review Articles

Top

CB1 Receptor Signaling in the Brain: Extracting Specificity from Ubiquity OPEN

Arnau Busquets-Garcia, Jaideep Bains and Giovanni Marsicano

Neuropsychopharmacology 2018 43: 4-20; advance online publication, September 1, 2017; 10.1038/npp.2017.206

Abstract | Full Text

The Role of the Endocannabinoid System and Genetic Variation in Adolescent Brain Development

Heidi C Meyer, Francis S Lee and Dylan G Gee

Neuropsychopharmacology 2018 43: 21-33; advance online publication, July 7, 2017; 10.1038/npp.2017.143

Abstract | Full Text

Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective

Ziva D Cooper and Rebecca M Craft

Neuropsychopharmacology 2018 43: 34-51; advance online publication, July 17, 2017; 10.1038/npp.2017.140

Abstract | Full Text

The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain

Giulia Donvito, Sara R Nass, Jenny L Wilkerson, Zachary A Curry, Lesley D Schurman, Steven G Kinsey and Aron H Lichtman

Neuropsychopharmacology 2018 43: 52-79; advance online publication, August 31, 2017; 10.1038/npp.2017.204

Abstract | Full Text

Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder

Matthew N Hill, Patrizia Campolongo, Rachel Yehuda and Sachin Patel

Neuropsychopharmacology 2018 43: 80-102; advance online publication, July 26, 2017; 10.1038/npp.2017.162

Abstract | Full Text

Endocannabinoid Regulation of Reward and Reinforcement through Interaction with Dopamine and Endogenous Opioid Signaling

J M Wenzel and J F Cheer

Neuropsychopharmacology 2018 43: 103-115; advance online publication, June 27, 2017; 10.1038/npp.2017.126

Abstract | Full Text

Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure

Leigh V Panlilio and Zuzana Justinova

Neuropsychopharmacology 2018 43: 116-141; advance online publication, August 28, 2017; 10.1038/npp.2017.193

Abstract | Full Text

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol

Douglas L Boggs, Jacques D Nguyen, Daralyn Morgenson, Michael A Taffe and Mohini Ranganathan

Neuropsychopharmacology 2018 43: 142-154; advance online publication, September 6, 2017; 10.1038/npp.2017.209

Abstract | Full Text

Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?

Cecilia J Hillard

Neuropsychopharmacology 2018 43: 155-172; advance online publication, June 27, 2017; 10.1038/npp.2017.130

Abstract | Full Text

The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal

Christina A Brezing and Frances R Levin

Neuropsychopharmacology 2018 43: 173-194; advance online publication, September 6, 2017; 10.1038/npp.2017.212

Abstract | Full Text

US Epidemiology of Cannabis Use and Associated Problems OPEN

Deborah S Hasin

Neuropsychopharmacology 2018 43: 195-212; advance online publication, August 30, 2017; 10.1038/npp.2017.198

Abstract | Full Text

Hot Topics

Top

Toward a Translationally Relevant Preclinical Model of Cannabis Use

Ryan J McLaughlin

Neuropsychopharmacology 2018 43: 213; 10.1038/npp.2017.191

Full Text

Setting the Legal Age for Access to Cannabis in Canada: Bridging Neuroscience, Policy, and Prevention

Rebecca J Haines-Saah and Emily K Jenkins

Neuropsychopharmacology 2018 43: 213-214; 10.1038/npp.2017.234

Full Text

Medical Cannabis Research: Issues and Priorities

Mark A Ware

Neuropsychopharmacology 2018 43: 214-215; 10.1038/npp.2017.222

Full Text

Selective Adenylyl Cyclase Type 1 Inhibitors as Potential Opioid Alternatives For Chronic Pain

Val J Watts

Neuropsychopharmacology 2018 43: 215-216; 10.1038/npp.2017.190

Full Text

Novel Synthetic Opioids and Overdose Deaths: Tip of the Iceberg?

Michael H Baumann and Gavril W Pasternak

Neuropsychopharmacology 2018 43: 216-217; 10.1038/npp.2017.211

Full Text

Opioidergic regulation of pain and pleasure in human social relationships

Lauri Nummenmaa and Tomi Karjalainen

Neuropsychopharmacology 2018 43: 217-218; 10.1038/npp.2017.200

Full Text

Modulating Amygdala–Hippocampal Network Communication: A Potential Therapy for Neuropsychiatric Disorders

Jie Zheng and Jack J Lin

Neuropsychopharmacology 2018 43: 218-219; 10.1038/npp.2017.201

Full Text

Modeling Non-Syndromic Autism with Human-Induced Pluripotent Stem Cells

Luke AD Bury and Anthony Wynshaw-Boris

Neuropsychopharmacology 2018 43: 219-220; 10.1038/npp.2017.195

Full Text

Innovative Therapeutic Intervention For Opioid Use Disorder

F Gerard Moeller and Kathryn A Cunningham

Neuropsychopharmacology 2018 43: 220-221; 10.1038/npp.2017.192

Full Text

The Ketamine Metabolite 2R,6R-Hydroxynorketamine Blocks NMDA Receptors and Impacts Downstream Signaling Linked to Antidepressant Effects

Ege T Kavalali and Lisa M Monteggia

Neuropsychopharmacology 2018 43: 221-222; 10.1038/npp.2017.210

Full Text

Cognitive Signaling in Cerebellar Granule Cells

Mark J Wagner

Neuropsychopharmacology 2018 43: 222-223; 10.1038/npp.2017.186

Full Text

The Promise of Genome Editing for Modeling Psychiatric Disorders

Stephanie PB Caligiuri and Paul J Kenny

Neuropsychopharmacology 2018 43: 223-224; 10.1038/npp.2017.197

Full Text

Aggression Addiction and Relapse: A New Frontier in Psychiatry

Sam A Golden and Yavin Shaham

Neuropsychopharmacology 2018 43: 224-225; 10.1038/npp.2017.173

Full Text

Computational Approaches to Behavior Analysis in Psychiatry

Cheryl M Corcoran and Guillermo A Cecchi

Neuropsychopharmacology 2018 43: 225-226; 10.1038/npp.2017.188

Full Text

Cannabinoid Receptor 1 Positive Allosteric Modulators for Posttraumatic Stress Disorder

Anantha Shekhar and Ganesh A Thakur

Neuropsychopharmacology 2018 43: 226-227; 10.1038/npp.2017.230

Full Text

Integrating ‘Omics’ Approaches to Prioritize New Pathogenetic Mechanisms for Mental Disorders OPEN

Annamaria Cattaneo and Carmine M Pariante

Neuropsychopharmacology 2018 43: 227-228; 10.1038/npp.2017.221

Full Text

A Translational Model to Assess Sign-Tracking and Goal-Tracking Behavior in Children

Michelle A Joyner, Ashley N Gearhardt and Shelly B Flagel

Neuropsychopharmacology 2018 43: 228-229; 10.1038/npp.2017.196

Full Text

The Role of Mitochondrial Glutamate Metabolism in Cognitive Development and Disease

Ozan Baytaş and Eric M Morrow

Neuropsychopharmacology 2018 43: 229-230; 10.1038/npp.2017.202

Full Text

Cross-Species Neurophysiological Biomarkers of Attentional Dysfunction in Schizophrenia: Bridging the Translational Gap

Jared W Young and Gregory A Light

Neuropsychopharmacology 2018 43: 230-231; 10.1038/npp.2017.218

Full Text

Please note that you need to be a subscriber or site-license holder to enjoy full-text access to Neuropsychopharmacology. In order to do so, please purchase a subscription.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature